TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Takara Bio Inc. ( (JP:4974) ) has issued an update.
Takara Bio Inc. announced its decision to merge with its wholly owned subsidiary, ViSpot, Inc., effective May 1, 2025. The merger aims to streamline management and boost business expansion, with Takara Bio remaining as the surviving entity. ViSpot, which specializes in viral safety testing services, was previously in a state of insolvency, but this issue was resolved prior to the merger. The merger is expected to have a minor impact on Takara Bio’s consolidated business performance.
More about Takara Bio Inc.
Takara Bio Inc. operates in the biotechnology industry, specializing in the manufacturing and sales of reagents and instruments, contract development and manufacturing organization (CDMO) services, and gene therapy business. The company is focused on expanding its market presence through strategic mergers and acquisitions.
YTD Price Performance: -17.43%
Average Trading Volume: 317,187
Technical Sentiment Signal: Buy
Current Market Cap: Yen104.4B
For an in-depth examination of 4974 stock, go to TipRanks’ Stock Analysis page.